[Investigation on the role and mechanism of prostagland in D2 synthase in non-small cell lung cancer].
Objective: To investigate prostaglandin D2 synthase (PTGDS) expression in non-small cell lung carcinoma (NSCLC) and clarify whether PTGDS could be a biomarke. Methods: Firstly, the protein expression level of PTGDS in adenocarcinoma (ADC) and squamous cell carcinoma (SCC) were analyzed respectively through Gene Expression Omnibus (GEO)dataset. Then, the results were verified by using tissue microarray (TMA). At last, in order to explore the inner mechanism, lung adenocarcinoma cell lines A549 and Calu-3 were selected to over-express PTGDS, and then transwell chamber assay and Western blotting were used to detect associated changes. Results: PTGDS expression is down-regulated in both ADC and SCC, however, no statistical difference has been found between the two groups, and PTGDS was only related to the progression of ADC. Furthermore, After over-expression of PTGDS, the invasiveness of ADC cells was significantly decreased. Western blotting showed that the inner mechanisms may be related to mitogen-activated protein kinase (MAPK) signal pathway. Conclusions: This study revealed that PTGDS was down-regulated in NSCLC and only related to the development of ADC. It may be a potential biomarker for the diagnosis and prognosis of NSCLC. However, whether it could be used for the treatment of NSCLC still needs more research.